Latest1 information on COVID-19
©2022 Stanford Medicine
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
Not Recruiting
Trial ID: NCT01457768
Purpose
This Registry is designed to obtain long term data on participants who have failed to achieve
sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent
(OAV) in a previous Gilead-sponsored hepatitis C virus (HCV) study.
Official Title
A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection
Stanford Investigator(s)
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Eligibility
Key Inclusion Criteria:
- Have previously participated in a Gilead-sponsored hepatitis C study and received at
least one Gilead OAV
- Have failed to achieve an SVR in a previous Gilead-sponsored study, as defined in the
original treatment protocol
- Provide written, informed consent
- Be willing and able to comply with the visit schedule
Key Exclusion Criteria:
- Individuals planning to start a new course of hepatitis C therapy including any
investigational drug or device during the course of the follow-up Registry
- History of clinically significant illness or any other major medical disorder that may
interfere with follow-up, assessments or compliance with the protocol
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mindie H. Nguyen, MD
650-498-7878